PURE Bioscience Reports Fiscal 2018 Third Quarter and Nine-Month Financial Results

Update on PURE’s Food Safety Solutions Outlook for Calendar 2018

SAN DIEGO–(BUSINESS WIRE)–$PURE #PUREPURE Bioscience, Inc. (OTCQB:
PURE
), creator of the patented non-toxic silver
dihydrogen citrate (SDC)
antimicrobial, today reported financial results for the fiscal third
quarter and nine-month period ended April 30, 2018.

Q3: Summary of Results of Operations

  • Revenues for the fiscal third quarter ended April 30, 2018 increased
    15% to $390,000, compared with revenues of $338,000 in the prior year
    fiscal third quarter. The increase was due to new customer adoption.

    • Core food safety revenues for the fiscal third quarter ended 2018
      increased 35% as compared with food safety revenues in the fiscal
      third quarter ended 2017.
  • Net loss for the fiscal third quarter in 2018 was $1.69 million, as
    compared with $1.74 million for fiscal third quarter in 2017. Net
    loss, excluding derivative expense, and share-based compensation, for
    the third fiscal quarter in 2018 was $1.1 million, as compared with
    $1.3 million for the third quarter in 2017.
  • Net loss per share was ($0.02) as compared with ($0.03) for the fiscal
    third quarter ended 2018 and 2017.
  • Gross margin was 57% during the third quarter of fiscal 2018 as
    compared with 61% during the same period in fiscal 2017. The decrease
    in gross margin percentage was primarily attributable to the sale of
    lower margin formulations and packaging configurations of our products
    during the quarter ended April 30, 2018, as compared with the prior
    period.

Nine Months: Summary of Results of Operations

  • Revenues for the nine-months ended April 30, 2018 decreased 4% to
    $1.27 million compared with prior year nine-month revenues of $1.32
    million.

    • Core food safety revenues for the nine months ended 2018 decreased
      8% as compared with food safety revenues in the nine months ended
      2017. The decline in both total and food safety revenues was due
      to timing of product orders, as the initial system-wide stocking
      order from Chipotle occurred in fiscal 2017 Q1.

      • Food safety revenues were up 44% year over year, excluding the
        Chipotle initial stocking order from Q1 2017.
  • Net loss for the nine months ended April 30, 2018, was $6.1 million
    compared with $4.4 million for the nine month period in 2017. Net
    loss, excluding derivative income, inducement expense and share-based
    compensation, for the nine months ended April 30, 2018 was $3.7
    million, as compared with $3.9 million for the nine month period in
    2017.
  • Net loss per share was ($0.09) as compared with ($0.07) for the nine
    months ended fiscal 2018 and 2017.
  • Gross margin was 63% during the first nine months of fiscal 2018 as
    compared with 60% during the same nine-month period in fiscal 2017.
    The increase in gross margin percentage was primarily attributable to
    the sale of higher margin formulations and packaging configurations of
    our products during the nine months ended April 30, 2018 as compared
    with the prior period.

Hank
R. Lambert
, CEO, said that, “We’ve experienced a robust start to
fiscal Q4 and look forward to ending our year with strong upward
momentum. Chipotle reorders for PURE® Hard Surface
disinfectant have begun to ramp, normalizing inventory turn. Our core
food safety revenues have shown consistent double digit quarterly
growth, thereby validating our strategic focus and the game changing
nature of our SDC-based solutions. Taylor Farms has expanded use of PURE
Control® in two of its produce processing plants – and is
executing on its plan for implementation into its 14 plant network. In
addition, we continue to generate growing sales of PURE Hard Surface as
a truck sanitization solution into the Sysco food transportation
network, a new vertical launched earlier this fiscal year.

“Addressing the expense side of the business, we’ve taken steps to
significantly reduce our overhead. This combination of revenue momentum
and expense control fuels our confidence that we will achieve a cash
flow breakeven annual revenue run rate of approximately $7 million in
calendar Q1 2019,” concluded Lambert.

2018 Fiscal Third Quarter Financial Results Conference Call

The Participant Dial-In Number for the conference call is 1-631-891-4304.
Participants should dial in to the call at least five minutes before
1:30pm PDT (4:30pm ET) on June 13, 2018. The call can also be accessed
“live” online at http://public.viavid.com/index.php?id=129853.

A replay of the recorded call will be available for 90 days on the
Company’s website (http://www.purebio.com/investors/events-presentations/).
You can also listen to a replay of the call by dialing 1-844-512-2921 (international
participants dial 1-412-317-6671) starting June 13, 2018, at 7:30pm ET
through June 20, 2018 at 11:59pm ET. Please use PIN Number 10004941.

About PURE Bioscience, Inc.

PURE Bioscience, Inc. is focused on developing and commercializing our
proprietary antimicrobial products primarily in the food safety arena —
providing solutions to the health and environmental challenges of
pathogen and hygienic control. Our technology platform is based on
patented stabilized ionic silver, and our initial products contain
silver dihydrogen citrate, or SDC. SDC is a broad-spectrum, non-toxic
antimicrobial agent, which offers 24-hour residual protection and
formulates well with other compounds. As a platform technology, SDC is
distinguished from existing products in the marketplace because of its
superior efficacy, reduced toxicity and it mitigates bacterial
resistance. PURE is headquartered in El Cajon, California (San Diego
metropolitan area). Additional information on PURE is available at www.purebio.com.

Forward-looking Statements

Any statements contained in this press release that do not describe
historical facts may constitute forward-looking statements as that term
is defined in the Private Securities Litigation Reform Act of 1995.
Forward-looking statements inherently involve risks and uncertainties
that could cause our actual results to differ materially from any
forward-looking statements. Factors that could cause or contribute to
such differences include, but are not limited to, the Company’s failure
to implement or otherwise achieve the benefits of its proposed business
initiatives and plans; acceptance of the Company’s current and future
products and services in the marketplace, including the Company’s
ability to convert successful evaluations and tests for PURE Control
into customer orders and customers continuing to place product orders as
expected and to expand their use of the Company’s products; the
Company’s ability to raise the funding required to support its continued
operations and the implementation of its business plan; the ability of
the Company to develop effective new products and receive required
regulatory approvals for such products, including the required data and
regulatory approvals required to use its SDC-based technology as a
direct food contact processing aid in raw meat processing and to expand
its use in OLR poultry processing; competitive factors, including
customer acceptance of the Company’s SDC-based products that are
typically more expensive than existing treatment chemicals; dependence
upon third-party vendors, including to manufacture its products; and
other risks detailed in the Company’s periodic report filings with the
Securities and Exchange Commission (the SEC), including its Form 10-K
for the fiscal year ended July 31, 2017 and Form 10-Q for the third
fiscal quarter ended April 30, 2018. You should not place undue reliance
on these forward-looking statements, which speak only as of the date of
this press release. By making these forward-looking statements, the
Company undertakes no obligation to update these statements for
revisions or changes after the date of this release.

PURE Bioscience, Inc.
Condensed Consolidated Balance Sheets
 
  April 30, 2018   July 31, 2017
(Unaudited)
Assets
Current assets
Cash and cash equivalents $ 1,018,000 $ 1,640,000
Accounts receivable 192,000 297,000
Inventories, net 275,000 273,000
Restricted cash 75,000 75,000
Prepaid expenses   52,000     174,000  
Total current assets 1,612,000 2,459,000
Property, plant and equipment, net 487,000 548,000
Patents, net   701,000     822,000  
Total assets $ 2,800,000   $ 3,829,000  
Liabilities and stockholders’ equity
Current liabilities
Accounts payable $ 486,000 $ 426,000
Accrued liabilities 137,000 249,000
Derivative liabilities       1,853,000  
Total current liabilities 623,000 2,528,000
Deferred rent   15,000     11,000  
Total liabilities   638,000     2,539,000  
Commitments and contingencies
Stockholders’ equity
Preferred stock, $0.01 par value: 5,000,000 shares authorized, no
shares issued and outstanding
Common stock, $0.01 par value: 100,000,000 shares authorized,
68,076,408 shares issued and outstanding at April 30, 2018, and
63,093,153 shares issued and outstanding at July 31, 2017
681,000 631,000
Additional paid-in capital 117,021,000 110,141,000
Accumulated deficit   (115,540,000 )   (109,482,000 )
Total stockholders’ equity   2,162,000     1,290,000  
Total liabilities and stockholders’ equity $ 2,800,000   $ 3,829,000  
 
 
PURE Bioscience, Inc.
Condensed Consolidated Statements of Operations
(Unaudited)
 
  Nine Months Ended  

Three Months Ended

April 30, April 30,
  2018       2017     2018       2017  
Net product sales $ 1,265,000 $ 1,316,000 $ 390,000 $ 338,000
Operating costs and expenses
Cost of goods sold 473,000 531,000 166,000 132,000
Selling, general and administrative 4,102,000 3,972,000 1,239,000 1,302,000
Research and development 381,000 684,000 117,000 222,000
Share-based compensation   1,975,000     723,000     579,000     275,000  
Total operating costs and expenses   6,931,000     5,910,000     2,101,000     1,931,000  
Loss from operations   (5,666,000 )   (4,594,000 )   (1,711,000 )   (1,593,000 )
Other income (expense)
Inducement to exercise warrants (876,000 )
Change in derivative liabilities 459,000 153,000 (147,000 )
Interest expense, net (3,000 ) (4,000 ) (1,000 ) (1,000 )
Other income, net   28,000     28,000     20,000     3,000  
Total other income (expense)   (392,000 )   177,000     19,000     (145,000 )
Net loss $ (6,058,000 ) $ (4,417,000 ) $ (1,692,000 ) $ (1,738,000 )
Basic and diluted net loss per share $ (0.09 ) $ (0.07 ) $ (0.02 ) $ (0.03 )
Shares used in computing basic and diluted net loss per share   66,996,085     63,718,152     68,057,658     62,679,644  
 
 
PURE Bioscience, Inc.
Condensed Consolidated Statements of Cash Flows
(Unaudited)
 
  Nine Months Ended
April 30,
  2018       2017  
Operating activities
Net loss $ (6,058,000 ) $ (4,417,000 )
Adjustments to reconcile net loss to net cash used in operating
activities:
Share-based compensation 1,975,000 723,000
Amortization of stock issued for services 115,000 108,000
Depreciation and amortization 213,000 204,000
Gain on inventory recovery (19,000 )
Change in fair value of derivative liabilities (459,000 ) (153,000 )
Inducement to exercise warrants 876,000
Changes in operating assets and liabilities:
Accounts receivable 105,000 78,000
Inventories 17,000 2,000
Prepaid expenses 60,000 (5,000 )
Accounts payable and accrued liabilities (52,000 ) 58,000
Deferred rent   4,000     9,000  
Net cash used in operating activities   (3,223,000 )   (3,393,000 )
Investing activities
Investment in patents (12,000 ) (11,000 )
Purchases of property, plant and equipment   (19,000 )   (205,000 )
Net cash used in investing activities   (31,000 )   (216,000 )
Financing activities
Net proceeds from the exercise of warrants 2,632,000 80,000
Net proceeds from the sale of common stock       1,049,000  
Net cash provided by financing activities   2,632,000     1,129,000  
Net decrease in cash and cash equivalents (622,000 ) (2,480,000 )
Cash and cash equivalents at beginning of period   1,640,000     5,194,000  
Cash and cash equivalents at end of period $ 1,018,000   $ 2,714,000  
Supplemental disclosure of cash flow information
Cash paid for taxes $   $ 2,000  
Noncash Investing and Financing activities
Warrant liabilities removed due to settlements $ 1,394,000   $ 8,000  
Common stock issued for prepaid services $ 51,000   $  
Restricted stock unit cancelation $   $ 38,000  

Contacts

Hank Lambert, CEO
PURE Bioscience, Inc.
619-596-8600 ext.103
hlambert@purebio.com
or
Terri
MacInnis, VP of IR
Bibicoff + MacInnis, Inc.
818-379-8500
terri@bibimac.com
or
Tom
Hemingway
Redwood Investment Group
714-978-4425
tomh@redwoodfin.com